{"url_path":"/sec/inbx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000027-index.html","accession_number":"0002007919-26-000027","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000027-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":54,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nInsider Trading Arrangements\n\nDuring the quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.\n\n31"}